Synonym
LAS101057; LAS-101057; LAS 101057.
IUPAC/Chemical Name
N-(5-(3-fluoropyridin-4-yl)-6-(pyridin-3-yl)pyrazin-2-yl)cyclopropanecarboxamide
InChi Key
XUYURJQIMYCWBB-UHFFFAOYSA-N
InChi Code
InChI=1S/C18H14FN5O/c19-14-9-21-7-5-13(14)17-16(12-2-1-6-20-8-12)23-15(10-22-17)24-18(25)11-3-4-11/h1-2,5-11H,3-4H2,(H,23,24,25)
SMILES Code
O=C(C1CC1)NC2=NC(C3=CC=CN=C3)=C(C4=C(F)C=NC=C4)N=C2
Purity
>95% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Biological target:
LAS101057 is a potent, selective, and orally efficacious A2B receptor antagonist.
In vitro activity:
Given that the A2B receptor is known to mediate the release of the pro-inflammatory cytokine IL-6 through a mechanism dependent on the cAMP/cAMP response element binding (CREB) signaling pathway, it was decided to test the effect of 17 (LAS101057) on NECA-induced IL-6 release in human primary dermal fibroblasts as an additional means of demonstrating blockade of A2B receptor function. In this assay, 17 effected a concentration-dependent down-regulation of IL-6 production with a potency (67% ± 2 at 100 nM) that was in a similar range to that seen in both the A2B receptor radioligand binding and cAMP assays.
Reference: ACS Med Chem Lett. 2010 Dec 20;2(3):213-8. https://pubmed.ncbi.nlm.nih.gov/24900298/
In vivo activity:
As shown in Figure 1, 17 (LAS101057) reduced the increase of lung resistance in mice induced by methacholine. LAS101057 was active in preventing methacholine-induced AHR at 3 mg/kg, and at 10 mg/kg it inhibited AHR to methacholine to a level virtually equal to that seen with dexamethasone at 1 mg/kg.
Reference: ACS Med Chem Lett. 2010 Dec 20;2(3):213-8. https://pubmed.ncbi.nlm.nih.gov/24900298/
|
Solvent |
mg/mL |
mM |
comments |
| Solubility |
| DMSO |
125.0 |
372.75 |
|
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.
Preparing Stock Solutions
The following data is based on the
product
molecular weight
335.34
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
Formulation protocol:
1. Eastwood P, Esteve C, González J, Fonquerna S, Aiguadé J, Carranco I, Doménech T, Aparici M, Miralpeix M, Albertí J, Córdoba M, Fernández R, Pont M, Godessart N, Prats N, Loza MI, Cadavid MI, Nueda A, Vidal B. Discovery of LAS101057: A Potent, Selective, and Orally Efficacious A2B Adenosine Receptor Antagonist. ACS Med Chem Lett. 2010 Dec 20;2(3):213-8. doi: 10.1021/ml100249e. PMID: 24900298; PMCID: PMC4018059.
In vitro protocol:
1. Eastwood P, Esteve C, González J, Fonquerna S, Aiguadé J, Carranco I, Doménech T, Aparici M, Miralpeix M, Albertí J, Córdoba M, Fernández R, Pont M, Godessart N, Prats N, Loza MI, Cadavid MI, Nueda A, Vidal B. Discovery of LAS101057: A Potent, Selective, and Orally Efficacious A2B Adenosine Receptor Antagonist. ACS Med Chem Lett. 2010 Dec 20;2(3):213-8. doi: 10.1021/ml100249e. PMID: 24900298; PMCID: PMC4018059.
In vivo protocol:
1. Eastwood P, Esteve C, González J, Fonquerna S, Aiguadé J, Carranco I, Doménech T, Aparici M, Miralpeix M, Albertí J, Córdoba M, Fernández R, Pont M, Godessart N, Prats N, Loza MI, Cadavid MI, Nueda A, Vidal B. Discovery of LAS101057: A Potent, Selective, and Orally Efficacious A2B Adenosine Receptor Antagonist. ACS Med Chem Lett. 2010 Dec 20;2(3):213-8. doi: 10.1021/ml100249e. PMID: 24900298; PMCID: PMC4018059.
1: Eastwood P, Esteve C, González J, Fonquerna S, Aiguadé J, Carranco I, Doménech
T, Aparici M, Miralpeix M, Albertí J, Córdoba M, Fernández R, Pont M, Godessart
N, Prats N, Loza MI, Cadavid MI, Nueda A, Vidal B. Discovery of LAS101057: A
Potent, Selective, and Orally Efficacious A2B Adenosine Receptor Antagonist. ACS
Med Chem Lett. 2010 Dec 20;2(3):213-8. doi: 10.1021/ml100249e. eCollection 2011
Mar 10. PubMed PMID: 24900298; PubMed Central PMCID: PMC4018059.
